What if you could correctly predict — nine times out of ten — that your drug will have the intended efficacy in a clinical trial?
Our unique discovery platform can do that. By isolating the tumor-causing biology and testing it against the full spectrum of a drug's effects in a biological system, we precisely match drugs to patients that could benefit. With 95% of all cancer patients represented and a screening throughput of hundreds of drugs per week, we enable precision oncology at scale.
We only use strictly necessary, first-party cookies on this job board. These are cookies that are necessary to deliver this service to you, or are necessary for Two Bear Capital to understand how it is being used. Read our Cookie Policy.